Transcript Providing Compassionate Care While Avoiding Common Mistakes

Understanding State Board Regulations:
Providing Compassionate Care While
Avoiding Common Mistakes
Joe Y. Kim, MD
Water’s Edge: Memorial’s Pain Relief Institute
Washington State
•
Follows Model Policy on the Use of Opioid
Analgesics in the Treatment of Chronic Pain
•
Federation of State Medical Boards
•
July 2013 (1997, 2003)
Washington State
•
Since 2004
•
1 in 4 in primary care settings, pain limits ADL’s
•
Undertreatment of pain is serious public health
problem
Inappropriate Management
•
Inadequate initial assessment for clinical indication
•
Inadequate monitoring
•
Inadequate attention to patient education/consent
•
Unjustified dose escalation: risks? alternatives?
Discipline
•
“Physicians should not fear disciplinary action
from the Board for ordering, prescribing,
dispensing or administering controlled
substances, including opioid analgesics, for a
legitimate medical purpose and in the course of
professional practice, when current best clinical
practices are met.”
Discipline
•
“The Board will not take discplinary action against
a physician for deviating from this Model Policy
when contemporaneous medical records show
reasonable cause for such a deviation.”
•
“The board will judge the validity of the
physician’s treatment of a patient on the basis of
available documentation, rather than solely on
the quantity and duration of medication
administered”.
Guidelines
•
Understanding Pain:
•
Patient Evaluation and Risk Stratification
•
Development of a Treatment Plan/Goals
•
Informed Consent/Treatment Agreement
Guidelines
•
Initiating an Opioid Trial
•
Ongoing Monitoring and Adapting the
Treatment Plan
•
Periodic Drug Testing
•
Consultation and Referral
Guidelines
•
Discontinuing Opioid Therapy
•
Medical Records
•
Compliance with Controlled Substance Laws
and Regulations
Methadone
•
Increased rate of methadone related deaths
•
QTc: pre, 3days, annual
•
450-500 ms discuss (debate)
•
“No evidence has been found to support the
use of the EKG for preventing cardiac
arrhythmias in methadone-treated opioid
dependents” Cochrane investigators
Methadone
•
Follow up sooner after:
•
•
Initiation or increase
Pharmacodynamics/kinetics
•
Analgesic action 6 hrs (morphine is opposite)
•
Full analgesic effects
•
•
Morphine conversion median 5 days (range 4-13)
•
May be 1-2 weeks
Long half-lfe/accumulation ==> delayed toxicity
Methadone
•
Equianalgesic for repetitive dosing smaller than
single-dose
•
65 y/o decreased clearance
•
No liver adjustments
•
Metabolites do not accumulate with renal failure
Methadone
•
Increased rate of methadone related deaths
What is the ideal opioid?
•
half-life, side effects, metabolites, etc…
What is the ideal opioid?
Oxycodone
No ceiling dose
Minimal side effects
Absence/minimal activce metabolite
Easy titration
Rapid onset
Short half-life
Long duration
Predictable pharmacokinetics
Random Considerations
•
T3/T4: ceiling effect 60mg/dose, max 360mg/day
•
Hyrdocodone: maximal daily 60mg/day?
•
Morphine: renal failure (M6G); rectal?
•
Oxymorphone: hepatic impairment
Random Considerations
•
Tapentadol (Nucynta): seizures, ICP, asthma
•
inhibit serotonin/NE reuptake
•
Tramadol: 5HT, cardiovascular, seizures, addiction
•
TCA/MSO4: synergistic CNS/respiratory depression
Guidelines
•
Patient Evaluation and Risk Stratification
•
•
Indication/Evaluation
Assessment
•
Nature, intensity, treatments, comorbidities, function.
•
ROS, SH, FH (abuse), PE, labs?, SOAPP-R, ORT
•
All patients should be screened for depression/mental
health
Guidelines
•
Assessment
•
History of substance abuse: failure/harm
•
•
If possible, consult before therapy initiated.
Current abuse
•
Established in treatment/recovery program
•
Co-managed with addictions specialist
Terms
•
Tolerance
•
Dependence
•
Abuse
•
Addiction
Guidelines
•
Assessment
•
Brings in own pile of records
•
•
ask for records directly
PMP
Guidelines
•
Development of a treatment plan/goals
•
•
•
Goals
•
Improvement of pain and function
•
Improvement of pain associated symptoms
Avoidance of unnecessary/excessive use of meds
Revisited regularly
Guidelines
•
Development of a treatment plan/goals
•
Individualized
•
Supports selection of treatment
•
Objectives to evaluate progress
•
pain relief
•
physical/psychosocial function
Guidelines
•
•
Informed consent
•
Risks/benefits
•
Why change
Treatment agreement
•
Goals
•
Patient’s/physician’s responsibilities
Guidelines
•
Informed consent/Treatment agreement
•
Shared decision
•
Store/disposal
Guidelines
•
Initiating an Opioid Trial
•
Present as a trial (e.g. 90 days)
•
Evaluate benefit (pain/fxn/QOL) vs. harm
•
Lowest possible start dose
•
Short acting
Guidelines
•
Ongoing Monitoring and Adapting the
Treatment Plan
•
Collateral information: family, close contacts,
PMP
•
More frequently at first
•
Five A’s: Analgesia, Activity, Adverse Effects,
Aberrancy, Affect/mood
Guidelines
•
Ongoing Monitoring and Adapting the
Treatment Plan
•
Continue?
•
Progress towards goals (pain, fxn, QOL)
•
Absence of risks/adverse events
More meds
•
Psychotherapy
•
Rehabilitative
•
Injection
•
Surgery
•
Medications
More meds
•
Anti-inflammatory
•
Antidepressants
•
Membrane stabilizers
•
Muscle relaxants
•
Opioids
Escalations
•
Can be a sign of use disorder/diversion
•
•
Good time to get UDS
“halftime” rule
High doses
•
200mg (MED) in 2010, lower now
•
Concerns
•
Hyperalgesia
•
Neuroendocrine
•
Immunosuppression
Guidelines
•
Periodic Drug Testing/Screening
•
Clinical judgement > recommendations
•
Discuss in supportive fashion
•
Pill count “useful”
•
PMP “highly recommended”
Opioid Rotation
•
Intolerable side effects
•
Inadequate benefit
•
25-50% reduction
Rotation
•
Total 24-hour dose
•
Calculate new dose
•
50-65% got incomplete cross-tolerance
•
Consider rescue
Rotation
•
Fentanyl 50% decrease in 17 hours
•
Calculate new dose
•
50-65% got incomplete cross-tolerance
•
Consider rescue
Guidelines
Periodic Drug Testing/Screening
•
•
Unsatisfactory progress
•
Intervention needed:
•
early refill
•
multiple lost/stolen rx
•
physician shopping
•
intoxication/impairment
•
pressuring/threatening behavior
•
illicit/unprescribed drugs
Guidelines
•
Periodic Drug Testing/Screening
•
Intervention needed:
•
Behavior suggesting RECURRING misuse
•
self-increase dose
•
deteriorating function
•
failure to comply to the treatment plan
Guidelines
•
Periodic Drug Testing
•
“Firm response”
•
Forgery
•
Obvious impairment
•
abusive/assaultive behavior
Transit times (inexact)
Rapid:
•
•
EtOH 7-12 hrs
•
Pentobarbitol (24h)
•
Propoxyphene 6-48 hrs
Transit times
Fast:
•
•
(Meth) Amphetamine 48 hrs
•
Codeine 48 hrs
•
Heroine 48 hrs
•
Cocaine metabolites 2-4 days
•
Hydromorphone 2-4 days
•
Methadone 3 days
•
Short-acting BZ’s 3days
•
Long-term/heavy 30 d
Transit times
Long
•
•
PCP 8 days
•
Phenobarbital 3 wks
•
Long-acting BZ’s 30 days
Guidelines
•
Consultation and Referral
•
•
Pain, psychiatry, addiction, or mental health specialist “if
needed”
•
History of substance abuse
•
Co-occuring mental health disorder
Know treatment options in treatment programs for
addictions
Guidelines
Discontinuing Opioid Therapy
•
•
Regularly weigh benefits/risks
•
Discontinue
•
resolution
•
intolerable side effects
•
inadequate analgesia
•
failure to improve QOL
•
significant aberrancy
Guidelines
•
Discontinuing Opioid Therapy
•
Structured tapering regimen
•
Withdrawal
•
•
Addiction specialist or physician
Not the end (direct care or referral)
Weaning off
•
Repeated aberrant drug-related behaviors
•
Diversion
•
Intolerable side effects
•
No progress towards goals
“More Serious”
•
Repeatedly non adherent
•
Cocaine
•
Unprescribed opioids
•
Doctor Shopping
•
Unprescribed opioids
•
Morphine example
“Non-serious”
•
1-2 unauthorized dose escalations
•
Alcohol
Wean off
•
Rehabilitation setting ideal
•
Addiction
•
Addiction treatment made available
•
Follow-up
•
Non-opioid pain management
Wean off
•
Slow: 10%/ week
•
Rapid: 25-50% every few days
•
At higher doses, can be more rapid
•
When get to lower doses, slow down
Guidelines
•
Medical Records
•
Copies of the signed informed consent and treatment agreement
•
Patient’s medical history
•
Results of physical exam and laboratory tests
•
Results of risk assessment (e.g. screen tools)
•
Description of treatments provided
•
Instructions to the patient (e.g. risks, benefits)
Guidelines
•
Medical Records
•
Results of ongoing monitoring of patient progress
(pain/fxn)
•
Notes on evaluation/consultations of specialists
•
Any other supporting information to support
•
Authorization of release of information
Universal Precautions
•
1. Make a diagnosis with an appropriate differential
•
2. Conduct a patient assessment, including risk for substance
use disorders
•
3. Discuss the proposed treatment plan with the patient and
obtain informed consent
•
4. Have a written agreement that sets forth the expectations
and obligations of both the patient and treating physician
•
5. Initiate an appropriate trial of opioid therapy, with or
without adjunctive medications
Universal Precautions
•
6. Perform regular assessments of pain and function.
•
7. Reassess the patient’s pain score and level of function
•
8. Regularly evaluate the patient in terms of the “5 A’s”
•
9. Periodically review the pain diagnosis and any comorbid
conditions (including substance use disorders) and adjust
the treatement regimen accordingly
•
10. Keep careful and complete recored of the initial
evaluation and each follow up visit.
State Website
•
Can I drink alcohol while taking pain medication?
•
•
“Talk to your healthcare provider. Alcohol may have
unintended consequences…”
If a patient has been at 140 mg MED for several years,
do I need to consult a pain specialist?
•
“No, For a patient with stable pain and function, on a
non-escalating dosage of opioids, the consultation
requirement would not be required as long as the
practitioner documents these items.”
Scoping the Addict
•
Most strongly predictive factor:
•
personal/family history of alcohol/drug abuse.
•
Younger
•
Psychiatric history
Scoping the Addict
•
Travel
•
Escalation of dose
•
Focus on one medication
•
Affect
•
End of week refill
The “High Risk Patient”
•
History of drug abuse
•
Psychiatric issues
•
Serious aberrant drug-related behaviors
The “High Risk Patient”
•
Benefits outweigh risks
•
“Strongly Consider”
•
Mental health specialist
•
Addiction specialist
The “High Risk Patient”
•
Referral/change/discontinue
•
Precise prescription
•
4 strikes and you’re out:
How often to visit with?
•
Stable, Low risk: 3-6 months
•
High risk: up to weekly
•
addictive disorder
•
job requiring mental acuity
•
elderly
•
social/psychiatric/medical
The “High Risk Patient”
•
Change
•
More frequent/intense
•
Tapering (permanent/temporary)
•
Psychological therapies
•
Nonopioid treatment
The “High Risk Patient”
•
Discontinue
•
Diversion, forgery, stealing/buying
•
Serious aberrant behavior
•
•
Injecting oral meds
Dangerous/suicidal behavior
Driving
•
•
Effects (Especially at first, with increases, or
mixed)
•
Somnolence
•
Clouded mentation
•
Decreased Concentration
•
Slower reflexes/incoordination
Studies don’t show increase accidents
Driving
•
A person is guilty of driving while under the
influence of intoxicating liquor or any drug if the
person drives a vehicle within this state:
While the person is under the influence of or
affected by intoxicating liquor or any drug; or
While the person is under the combined influence of
or affected by intoxicating liquor and any drug.
Driving
•
A person is guilty of negligent driving in the first degree
if he or she operates a motor vehicle in a manner that is
both negligent and endangers or is likely to endanger any
person or property, and exhibits the effects of having
consumed liquor or an illegal drug.
•
However, legal entitlement to use the drug is a defense to
the charge of “negligent driving” [§46.61.5249 (1)(a)] if
the defendant had a valid prescription for the drug
consumed and had been consuming the drug according
to the prescription directions and warnings.